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ABSTRACT
The development of new growth hormone (GH) agonists and growth
hormone antagonists (GHAs) requires animal models for pre-clinical
testing. Ideally, the effects of treatment are monitored using the same
pharmacodynamic marker that is later used in clinical practice.
However, intact rodents are of limited value for this purpose because
serum IGF-I, the most sensitive pharmacodynamic marker for the
action of GH in humans, shows no response to treatment with
recombinant human GH and there is little evidence for the effects of
GHAs, except when administered at very high doses or when
overexpressed. As an alternative, more suitable model, we explored
pharmacodynamic markers of GH action in intact rabbits. We
performed the first validation of an IGF-I assay for the analysis of
rabbit serum and tested precision, sensitivity, linearity and recovery
using an automated human IGF-I assay (IDS-iSYS). Furthermore,
IGF-I was measured in rabbits of different strains, age groups and
sexes, and we monitored IGF-I response to treatment with
recombinant human GH or the GHA Pegvisomant. For a subset of
samples, we used LC-MS/MS to measure IGF-I, and quantitative
western ligand blot to analyze IGF-binding proteins (IGFBPs).
Although recovery of recombinant rabbit IGF-I was only 50% in the
human IGF-I assay, our results show that the sensitivity, precision
(1.7-3.3% coefficient of variation) and linearity (90.4-105.6%) were
excellent in rabbit samples. As expected, sex, age and genetic
background were major determinants of IGF-I concentration in
rabbits. IGF-I and IGFBP-2 levels increased after single and multiple
injections of recombinant human GH (IGF-I: 286±22 versus 
434±26 ng/ml; P<0.01) and were highly correlated (P<0.0001).
Treatment with the GHA lowered IGF-I levels from the fourth injection
onwards (P<0.01). In summary, we demonstrated that the IDS-iSYS
IGF-I immunoassay can be used in rabbits. Similar to rodents, rabbits
display variations in IGF-I depending on sex, age and genetic
background. Unlike in rodents, the IGF-I response to treatment 
RESEARCH ARTICLE
1Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Ludwig-
Maximilians University, 80336 Munich, Germany. 2Department of  Biology, Faculty
of  Sciences, University of  Isfahan, Isfahan 81746-73695, Iran. 3Department of
Immunology, Medical School, Isfahan University of  Medical Sciences, Isfahan
81746-73461, Iran. 4The Department of  Human Metabolism, The University of
Sheffield, Sheffield S10 2JF, UK. 5Immunodiagnostic Systems, Boldon, Tyne and
Wear NE35 9PD, UK. 6Ligandis GbR, Wilhelm-Stahl-Allee 2, 18196 Dummerstorf,
Germany. 7German Sport University Cologne, Institute of  Biochemisty/Center for
Preventive Doping Research, 50933 Cologne, Germany. 8Leibniz Institute for Farm
Animal Biology (FBN), Institute of  Genome Biology, 18196 Dummerstorf, Germany.
*Author for correspondence (Martin.Bidlingmaier@med.uni-muenchen.de)
This is an Open Access article distributed under the terms of  the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted
use, distribution and reproduction in any medium provided that the original work is properly
attributed.
Received 8 April 2014; Accepted 18 September 2014
with recombinant human GH or a GHA closely mimics the
pharmacodynamics seen in humans, suggesting that rabbits are a
suitable new model to test human GH agonists and antagonists.
KEY WORDS: Pharmacodynamic marker, Acromegaly, Growth
hormone deficiency, Animal model
INTRODUCTION
The development of pharmacological therapies to treat disorders of
the growth hormone and insulin-like growth factor (GH-IGF)
system allows better disease control and improves quality of life for
the affected individuals. For medical treatment of GH excess
(acromegaly), somatostatin analogs, dopamine agonists and a GH
antagonist (GHA) are established in routine clinical practice
(Katznelson et al., 2011). The synthesis of recombinant human GH
and its approval for clinical use improved the treatment of
individuals suffering from a GH deficiency (Kargi and Merriam,
2013). Pituitary secretion of GH is under the tight control of
different hypothalamic releasing and inhibiting factors. Although
GH itself is able to trigger biological responses in multiple target
tissues, the most important ‘downstream’ target of GH is the liver,
where GH stimulates IGF-I secretion through the activation of the
hepatic GH receptor. In turn, IGF-I modifies GH secretion through
a negative-feedback loop (Bielohuby et al., 2011a; Le Roith et al.,
2001; Møller and Jørgensen, 2009). Therefore, in GH excess and
GH insufficiency, the circulating concentration of IGF-I is
considered to be the most important biomarker for diagnosis and
monitoring of the disease (Clemmons, 2007; Keller et al., 2007). GH
replacement therapy aims to normalize endogenous IGF-I
concentrations, whereas effective treatment in individuals with
acromegaly is reflected by decreasing IGF-I concentrations (Kargi
and Merriam, 2013; Katznelson et al., 2011). Some studies also
suggest that circulating IGF-binding proteins (IGFBPs) are sensitive
markers for monitoring the disease and the treatment (Blum et al.,
1993; Zapf et al., 1990). Because IGFBPs are determinants of serum
IGF-I half-life, their measurement has been proposed to provide
additional information in intervention studies (Metzger et al., 2011).
Despite undisputed beneficial effects of existing pharmaceutical
options, novel potent substances are required because the available
medical treatment of GH excess is not effective in all individuals,
and treatment of GH deficiency still requires frequent injections.
Furthermore, existing treatment options are accompanied by
potential adverse effects, including increased hepatic enzymes,
swelling, lipodystrophy at the injection sites, diarrhea and nausea
(Péter et al., 2012; Petersenn et al., 2010; Sievers et al., 2009; van
der Lely et al., 2012). Therefore, the development of novel drugs
primarily aims to increase the potency of the substances, which
ideally should lead to better disease control, fewer side effects and
less frequent injections, or lower doses.
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Animal models are indispensable for the development of novel
drugs, and most commonly rodents are used to investigate the
properties of novel compounds. However, for the testing of substances
affecting the GH-IGF system, rodents only exhibit a limited
suitability. We and others have previously reported that in intact mice
and rats, IGF-I cannot be used as a reliable pharmacodynamic readout
to monitor exogenous GH administration (Bielohuby et al., 2011b;
Domené et al., 1993; Grönbladh et al., 2013). In contrast to the
situation in most other mammals, including humans, IGF-I is not
secreted at a higher rate in response to treatment with exogenous GH
in intact rodents (Bielohuby et al., 2011b). To avoid this issue,
hypophysectomized rodents are often used because the low
endogenous IGF-I concentrations in these animals can be potently
stimulated by treatment with exogenous GH. The major disadvantage
of using hypophysectomized mice or rats for testing of GH agonists
is that, in this artificial model, all pituitary hormones are lacking.
Thereby, the normal mammalian physiology is largely disturbed, and
it can not be predicted whether the absence of a physiological pituitary
function itself affects experiments using GH agonists.
By contrast, GHA and somatostatin analogs have been shown to
decrease circulating IGF-I concentrations in rodents (Courtland et
al., 2011; Divisova et al., 2006; Grønbaek et al., 2002). Notably,
GHAs per se (without previous treatments with exogenous GH)
decrease circulating IGF-I levels in rodents with intact pituitary
glands. However, it has been shown for the GHA Pegvisomant that,
compared with individuals with acromegaly, mice need
approximately 10- to 20-fold higher doses in order to induce a
significant reduction of circulating IGF-I (Kopchick et al., 2014;
Kopchick et al., 2002). With respect to somatostatin analogs, the
limited suitability of rodents as a pharmacodynamic model is also
evidenced by a recent study from Masyuk et al., in which the
authors report that rats treated with the somatostatin analog
Octreotide do not show a corresponding reduction in circulating
IGF-I (Masyuk et al., 2013). These examples highlight that rodents
display a unique regulation of the GH-IGF system to that of humans.
Considering these shortcomings of rodents as a model to develop
and test novel drugs in the field of GH-IGF-related disorders, we
speculated that rabbits, which are also commonly used as a
laboratory animal model, could be more suitable. This hypothesis
was further driven by a study from Cota and colleagues who have
previously generated a GH-overexpressing rabbit model (Costa et
al., 1998). Interestingly, this model shares many of the clinical
pathophysiological symptoms that are observed in individuals with
acromegaly (e.g. growth of specific parts of the head) but are absent
in GH-transgenic rodents (Costa et al., 1998). From an evolutionary
point of view, rabbits taxonomically belong to the order of
Lagomorpha, whereas mice and rats are classified as Rodentia.
Although rodent models are obviously justified and display
particular advantages for biomedical research, rabbits are also a
widely used research model offering particular strengths over
rodents (Daniel-Carlier et al., 2013; Flisikowska et al., 2011; Katter
et al., 2013; Thakur et al., 2000). In addition, tremendous progress
has been made in genetically modifying rabbits (Flisikowska et al.,
2011; Katter et al., 2013), enabling in-depth analysis of genome
function for future biomedical research. Thus, it can be assumed that
the accurate measurement of IGF-I in rabbits is also of relevance for
research beyond the treatment of GH-related disorders. For example,
it has only recently been suggested in human studies that IGF-I is
an important marker in malignant and metabolic diseases (Friedrich
et al., 2012; Key et al., 2010; Rosskopf et al., 2011).
Until today, no commercially available IGF-I assay has been
validated for the measurement of IGF-I in rabbit samples. Therefore,
the first step in the investigation of the suitability of IGF-I as a
pharmacodynamic marker of GH action in rabbits was to validate an
assay intended for human IGF-I in rabbit samples through analyzing
precision, sensitivity, linearity and recovery. For this purpose, we
used the automated human IGF-I assay (iSYS, IDS), which recently
has been extensively validated for human samples (Bidlingmaier et
al., 2014; Friedrich et al., 2014). The second step was to analyze the
physiological IGF-I and IGFBP concentrations in male and female
rabbits of different genetic strains and age groups. Finally, we
studied the suitability of rabbits as a new laboratory animal model
for studies of the GH-IGF system by testing how endogenous IGF-
I and IGFBP concentrations respond to treatment with either
recombinant human GH or the GH antagonist Pegvisomant.
RESULTS
Assay validation
A summary of the assay characteristics for the measurement of IGF-
I in rabbit samples is displayed in Table 1. The intra-assay variability
(precision) measured in rabbit serum displaying low, medium and
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TRANSLATIONAL IMPACT 
Clinical issue
Disorders of the growth hormone and insulin-like growth factor (GH-IGF)
system lead to severe diseases in humans. For example, acromegaly is
a life-threatening disease associated with GH-excess, mostly caused by
a GH-producing tumor in the pituitary gland, whereas GH-deficiency, as
seen in individuals with growth failure, is characterized by a lack of GH-
secretion, which can be congenital or acquired in childhood or adult life.
Existing pharmaceutical options for these disorders are not ideal
because the available treatments for GH-excess are not effective in all
affected individuals, whereas for GH-deficiency, more potent and long-
acting preparations are required. Thus, novel human GH-agonists and
GH antagonists (GHAs) displaying a higher efficacy and fewer side
effects are needed. Ideally, the effects of a treatment with a novel
substance are monitored in laboratory animals using a
pharmacodynamic biomarker that is also available in clinical practice. In
humans, serum IGF-I is the most sensitive biomarker for the diagnosis
and treatment surveillance of GH-related diseases. Mice and rats are the
most frequently used animal models for pre-clinical drug development,
but are of limited value for this indication because they show a unique
regulation of the GH-IGF system to that of humans. In this study, in order
to identify a more suitable, non-rodent animal model, pharmacodynamic
markers of GH action were investigated in rabbits.
Results
Owing to the lack of validated analytical platforms for the measurement of
IGF-I concentrations in rabbits, an automated human immunoassay was
tested for this purpose. The human IGF-I immunoassay exhibited
excellent sensitivity, precision and linearity in rabbit samples. Similar to
humans, sex, age and genetic background were major determinants of
circulating IGF-I concentrations in rabbits. Single and multiple injections
of recombinant human GH increased IGF-I concentrations, whereas
treatment with a GHA lowered IGF-I in rabbits. Thus, in these animals,
unlike in rodents, the IGF-I response to treatment with recombinant human
GH or a GHA closely mimics the pharmacodynamics seen in humans. 
Implications and future directions: 
These results indicate that rabbits are a suitable new model to test
human GH agonists and antagonists. For the first time, a validated
immunoassay is now available to measure changes in circulating IGF-I
together with a reference for detecting physiological IGF-I concentrations
in rabbits. By using this automated high-throughput platform, translational
research will be facilitated, because this system is already in use in many
routine laboratories. The possibility to measure IGF-I in rabbits, together
with the human-like behavior of IGF-I that was detected in response to
recombinant human GH and GHA, will aid the development of novel
therapeutics to treat pathological conditions of the GH-IGF system.
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high IGF-I concentrations was 2.55, 2.25 and 1.49%, respectively
(Table 1; supplementary material Table S1). The inter-assay
variability from six samples measured in five different assay runs
was found to be between 1.7 and 3.3% with a mean variability of
2.4% (Table 1; supplementary material Table S2). As described
previously for human samples (Bidlingmaier et al., 2014), for rabbit
samples, a functional sensitivity for a concentration of IGF-I below
10 ng/ml (precisely 7.3 ng/ml) was confirmed (Table 1;
supplementary material Table S3). Linearity of the assay for native
rabbit serum across the range 19-585 ng/ml for the sample with a
‘high’ starting concentration (rabbit serum A) and 15-190 ng/ml for
the sample with a ‘low’ starting concentration (rabbit serum B) was
well within accepted margins with mean observed to expected ratios
of 98.4% and 112%, respectively (Table 2). Overall, the ratio of the
observed to expected values in dilution linearity experiments using
rabbit samples with ‘high’ and ‘low’ starting concentrations
(concentration range 15-585 ng/ml) was 104.4%. Analysis of the
assay linearity using a small set of native human samples (human
serum A and B) yielded similar results to those observed with native
rabbit samples, and a mean percentage of the observed over
expected values of 107.6% and 116.9% for human serum A and B,
respectively, was calculated from measurement results (Table 2). A
more detailed study investigating the linearity of human samples for
measurement of IGF-I using this immunoassay is published
elsewhere (Bidlingmaier et al., 2014). With respect to dilution
linearity in native rabbit samples, serial dilutions of the three tested
native rabbit samples paralleled the dilution of the recombinant
standard material used (i.e. recombinant human IGF-I and
recombinant rabbit IGF-I; Fig. 1).
Recovery of IGF-I concentrations was assessed by spiking assay
buffer with either recombinant human IGF-I or recombinant rabbit
IGF-I. As expected, samples spiked with recombinant human IGF-
I (concentration range 19-1245 ng/ml) showed an excellent mean
recovery rate of 91.6% (range 81.1-101.1%). By contrast, the mean
recovery rate of recombinant rabbit IGF-I in assay buffer
(concentration range 12.6-3780 ng/ml) was only 47.4% (range 29.4-
71.4%; Table 3). Importantly, the lower recovery rate of
recombinant rabbit IGF-I in this immunoassay (around 50%) also
remained when using a different matrix and measuring native human
or rabbit serum that had been spiked with recombinant rabbit 
IGF-I. For human serum spiked with recombinant rabbit IGF-I, the
mean recovery rate upon measurement of IGF-I was 45.2% (range
40.4-53.2%), when using rabbit serum that had been spiked with
recombinant rabbit IGF-I, a mean recovery rate of 53.9% (range
47.2-65.3%) was observed. Non-parametric correlation and
regression analyses of the rabbit IGF-I measurements that had been
made by using immunoassay and liquid chromatography tandem
mass spectrometry (LC-MS/MS) revealed a good overall correlation
of measurement results, but the rabbit IGF-I concentrations were on
average 1.9-fold higher when measured by using LC-MS/MS
(Spearman’s ρ, 0.813; P<0.0001; Passing–Bablock: slope 0.684 and
intercept −78.3; Fig. 1B).
Biological variability
The genetic background, sex and age of rabbits clearly affected
circulating IGF-I concentrations. Analysis of samples from different
rabbit strains showed significantly higher IGF-I concentrations in
Chinchilla Bastard (CB) versus New Zealand White (NZW) rabbits
(P<0.01 in males and P<0.05 in females; Fig. 2A). In both strains,
female rabbits displayed significantly higher IGF-I concentrations
(male NZW, 200.6±9.0 ng/ml; female NZW, 285.8±25.9 ng/ml,
P<0.05; male CB, 265.7±16.3 ng/ml; female CB, 361.2±20.8 ng/ml,
P<0.001; Fig. 2A). Also, the age of rabbits significantly affected
IGF-I concentrations. Compared with 1-month-old rabbits, IGF-I
concentrations in 3-, 4- and 6-month-old male rabbits were
significantly lower (compared with the baseline concentrations at 
1 month: 1 month versus 3 months P<0.05, versus 4 months and
versus 6 months P<0.001, Fig. 3A). Similarly, IGF-I concentrations
also declined in female rabbits with advancing age (females
compared with the baseline concentrations at 1 month: 1 month
versus 3 and 4 months P<0.05, versus 6 months P<0.001). The
comparison of IGF-I concentrations in male and female rabbits
throughout the different age groups revealed significantly higher
IGF-I concentrations in female rabbits at the age of 2, 4 and 6
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Table 1. IDS-iSYS automated IGF-I immunoassay performance
characteristics for the measurement of IGF-I in rabbit serum 
Characteristic Measurement
Limit of detection 4.4 ng/ml
Limit of quantitation 7.3 ng/ml
Precision
Within-Run 1.1–3.3% CV (168–478 ng/ml)
Total 1.7–3.3% CV (173–396 ng/ml)
Linearity in rabbit serum with Mean: 98.4%
high starting concentrations (range: 90.4–105.6%; 19–585 ng/ml)
Linearity in human serum with Mean: 108%
high starting concentrations (range: 104.2–112.1%; 17–527 ng/ml)
Linearity in rabbit serum with Mean: 116.2%
low starting concentrations (range: 102.1–125%; 15–190 ng/ml)
Linearity in human serum with Mean: 117%
low starting concentrations (range: 105.3–133.3%; 12–151 ng/ml)
Recovery r-rbIGF-I Mean: 47.4%
(range: 29.4–71.4%; 12.6–3780 ng/ml)
Recovery r-hIGF-I Mean: 91.6%
(range: 81.1–101.1%; 19–1245 ng/ml)
Limit of detection as determined by Bidlingmaier et al. (Bidlingmaier et al.,
2014). CV, coefficient of variation; r-rbIGF-I, recombinant rabbit IGF-I; 
r-rhIGF-I, recombinant human IGF-I.
Table 2. Dilution linearity of rabbit and human serum with the IDS-
iSYS automated IGF-I immunoassay
Expected Measured Measured ÷ 
Dilution IGF-I conc. IGF-I conc. expected IGF-I 
Sample factor (x) (ng/ml) (ng/ml) conc. (%)
Rabbit serum A Neat – 585 –
1 in 2 293 299 102.0
1 in 4 146 145 99.3
1 in 8 73 66 90.4
1 in 16 37 35 94.6
1 in 32 18 19 105.6
Human serum A Neat – 527 –
1 in 2 264 275 104.2
1 in 4 132 142 107.6
1 in 8 66 71 107.6
1 in 16 33 37 112.1
1 in 32 16 17 106.3
Rabbit serum B Neat – 190 –
1 in 2 95 97 102.1
1 in 4 48 50 104.2
1 in 8 24 28 116.7
1 in 16 12 15 125.0
Human serum B Neat – 151 –
1 in 2 76 80 105.3
1 in 4 38 43 113.2
1 in 8 19 22 115.8
1 in 16 9 12 133.3
Conc., concentration.
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months (P<0.05, P<0.01 and P<0.001, respectively). No significant
differences between sexes were found when comparing IGF-I
concentrations from 1- and 3-month-old male and female rabbits
(Fig. 3A). Results from IGF-I analyses using LC-MS/MS confirmed
the age- and sex-specific differences in IGF-I concentrations, but the
absolute concentrations were approximately twofold higher
compared with the immunoassay measurements. By using LC-
MS/MS, 6-month-old male NZW rabbits had significantly lower
circulating IGF-I levels compared with 1-month-old male NZW
rabbits and significantly higher IGF-I compared with 6-month-old
female NZW rabbits (6-month-old male, 434.8±22.7 ng/ml versus
1-month-old male, 643.1±43.4 ng/ml, P<0.01 and versus 6-month-
old female: 542.8±31.5 ng/ml, P<0.05).
Circulating IGFBPs in rabbits of different sex, age and
genetic background
Analysis of serum IGFBPs by using quantitative western ligand
blotting revealed that, in rabbits, the IGFBP-2 concentrations were
quantitatively most abundant among the serum IGFBPs that we
measured (Fig. 2B). Overall, IGFBP-2 concentrations showed the
highest correlation with serum IGF-I concentrations (as measured
by using LC-MS/MS; Spearman’s ρ, 0:63, P<0.0001), followed by
a moderate correlation of IGFBP-4 with serum IGF-I (Spearman’s
ρ, 0:48, P<0.001). Circulating IGFBP-3 concentrations did not show
a significant correlation with serum IGF-I. With respect to sex and
genetic background, IGFBP-2 concentrations were significantly
(P<0.05) higher in 13-week-old NZW rabbits when compared with
age-matched male CB rabbits. IGFBP-3 and IGFBP-4
concentrations were not significantly affected by sex and genetic
background. Fig. 3B displays serum IGFBP-2 concentrations in
male and female NZW rabbits between 1 and 6 months of age. At
the age of 4 and 6 months, serum IGFBP-2 concentrations were
significantly higher in female rabbits compared with those of age-
matched males (at 4 months, P<0.001; at 6 months, P<0.01;
Fig. 3B). The other IGFBPs showed much lower variability across
this period.
Treatment of rabbits with a growth hormone antagonist
During treatment with the GHA Pegvisomant, IGF-I concentrations
in rabbits showed a continuous decline when compared with the
baseline concentration. After the fourth injection (i.e. 72 h into the
experiment), IGF-I concentrations were significantly (P<0.01) lower
when compared with those of controls, which received injections of
PBS. IGF-I concentrations also remained lower in GHA-treated
rabbits when compared with controls at 96, 120, 144 and 168 h (i.e.
after the fifth, sixth and seventh injection; Fig. 4A). Serum
concentrations of Pegvisomant increased until the fourth injection
to reach a maximum circulating concentration of 17990±2107
ng/ml. The GHA concentrations remained at this high level until the
last injection was given and then declined again (Fig. 4B). As
expected, the GHA was not detectable in the control group.
Supplementary material Fig. 1 shows that after a single
subcutaneous injection of the GHA, the serum GHA levels steadily
increased to reach the highest GHA concentrations after 8 h. In
comparison to recombinant human GH, the GHA was cleared much
more slowly from the circulation (supplementary material Fig. S1).
No effect of treatment with the GHA was observed on circulating
concentrations of IGFBP-2, IGFBP-3 and IGFBP-4 concentrations
(Fig. 4E; data not shown). Rabbits in the control group gained on
average 1.7±1.2% body weight during the experiment, rabbits
treated with the GHA displayed 2.2±1.6% lower body weight at the
end of the experiment. However, the difference in body weight
changes between controls and GHA-treated rabbits was not
statistically significant (Fig. 5). Liver weights were not significantly
different between control rabbits and rabbits that had been treated
with the GHA (controls 76.6±5.3 g versus GHA 80.1±8.0 g).
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Fig. 1. Dilution linearity and correlation analysis with LC-MS/MS measurements. (A) The dilution linearity of the assay with three different native rabbit
serum samples in relation to recombinant rabbit IGF-I (r-rbIGF-I) and recombinant human (r-hIGF-I) standard curves. (B) The correlation of rabbit IGF-I
measurements obtained using either the immunoassay or LC-MS/MS by using Passing–Bablock regression. Rabbit IGF-I concentrations were on average
approximately twofold higher when measured by using LC-MS/MS (Spearman’s ρ, 0.813; P<0.0001; Passing–Bablock: slope 0.684 and intercept −78.3). The
solid line shows the regression fit; the dotted lines show the 95% confidence limits of the regression fit.
Table 3. Recovery experiments of recombinant rabbit IGF-I
dissolved in assay buffer
IGF-I expected (ng/ml) IGF-I measured (ng/ml) Recovery (%)
3780.0 1113 29.4
756.0 688 44.7
504.0 378 44.8
315.0 338 43.8
189.0 226 45.0
126.0 138 47.6
94.5 85 47.6
63.0 60 49.2
31.5 45 50.8
12.6 31 71.4
Mean recovery 47.4
Dilutions of recombinant rabbit IGF-I were measured after confirmation of the
manufacturer’s concentration data by using LC-MS/MS analyses (expected
concentrations ranged between 12.6 and 3780 ng/ml). D
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Treatment of rabbits with recombinant human growth
hormone
In comparison to controls receiving PBS, even after only the first
injection, serum IGF-I was significantly higher in rabbits that had
been injected with recombinant human GH (versus controls after 
8 h P=0.054, after 12 h P<0.01). IGF-I concentrations declined after
the first injection with recombinant human GH, and 48 h after the first
injection, IGF-I concentrations were no longer higher in rabbits that
had been treated with recombinant human GH compared with
controls. After the second and third injection of recombinant human
GH (after 56 h and 72 h), IGF-I levels were significantly increased
again (Fig. 4C). The combination of IGF-I concentrations at time
points 24 h, 56 h and 72 h also resulted in significantly higher IGF-I
concentrations (+42.8%) in the group that had been treated with
recombinant human GH compared with those of controls (PBS
305.7±9.4 ng/ml versus recombinant human GH 436.7±15.1ng/ml;
P<0.001; Fig. 4C). In contrast to GHA, recombinant human GH
displayed a different pharmacodynamic behavior in the circulation.
Peak concentrations were detected 8 h after an injection, with rapidly
decreasing blood concentrations of recombinant human GH thereafter
(Fig. 4D; supplementary material Fig. S1). IGFBP-2 concentrations
in rabbits increased approximately threefold 24 h after being injected
with recombinant human GH (P<0.001; Fig. 4E). IGFBP-3 and
IGFBP-4 levels were not significantly affected by recombinant human
GH (data not shown). With respect to changes in body weight, the
recombinant-human-GH group showed the highest increases
(+9.9±2.0%) in body weight when comparing body weights at the
start of the treatment and after the last injection (Fig. 5). Compared
with those of controls and rabbits treated with GHA, the body weight
increases were significantly higher in rabbits that had been treated
with recombinant human GH (P<0.01).
DISCUSSION
We have demonstrated that in rabbits the measurement of IGF-I is a
suitable option to monitor the pharmacodynamic effects of treatment
with recombinant human GH and a GHA. Therefore, rabbits, in
combination with the measurement of treatment-induced changes in
circulating IGF-I, could easily be used as a new laboratory animal
model to develop novel GH agonists and GH antagonists. Similar to
humans and other mammals, rabbits also display a significant
variability in circulating IGF-I depending on age, sex and genetic
background. Furthermore, we have shown that the automated IDS-
iSYS human IGF-I immunoassay can be used to reliably measure
serum IGF-I concentrations in rabbits.
To our knowledge, this study is the first validation of a
commercially available automated IGF-I immunoassay for the
measurement of IGF-I in rabbits. We have decided to validate an
existing automated IGF-I immunoassay for use with rabbits because
the iSYS system is already used in many endocrine laboratories.
Thereby, translational investigations are facilitated and the same
analytical platform can be used for pre-clinical and clinical studies.
Furthermore, the automated system allows for high-throughput
analyses at reasonable costs, and the good performance of this
system for measurement of IGF-I in human samples has only
recently been published (Bidlingmaier et al., 2014). The low
variability of measurement results during testing for linearity, and
the intra- and inter-assay variability demonstrate that this assay can
reliably measure IGF-I concentrations in rabbits. During the
validation process, we confirmed a functional sensitivity of the assay
for measurement of IGF-I concentrations below 10 ng/ml in rabbits,
which allows us to measure even highly suppressed IGF-I
concentrations and to accurately measure diluted samples in cases
when the available volume is low. Overall, the validation of this
1267
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Fig. 2. Serum IGF-I and IGFBPs in rabbits. (A) Serum
IGF-I concentrations in male (blue) and female (red)
rabbits from 13-week-old NZW and CB rabbits (males,
n=7; females, n=8 for each strain). Data were analyzed
by using non-parametric Mann–Whitney-U tests,
*significant differences between male and female or
between New Zealand White (NZW) and Chinchilla
Bastard (CB) rabbits. Data are presented as box plots,
center lines represent the median, boxes represent the
middle 50% of data (interquartile range) and whiskers the
2.5-97.5 percentiles (*P<0.05, **P<0.01). (B) Analysis of
serum IGFBPs by using quantitative western ligand
blotting in male (blue) and female (red) rabbits from 13-
week-old NZW and CB rabbits (males, n=7; females, n=8
for each strain). The analyses revealed that, in rabbits,
the IGFBP-2 concentrations are quantitatively most
abundant among the serum IGFBPs measured. With
respect to sex and genetic background, IGFBP-2
concentrations were significantly (P<0.05) higher in 13-
week-old NZW rabbits when compared with age-matched
male CB rabbits. IGFBP-3 and IGFBP-4 were not
significantly affected by sex or genetic background. Data
are presented as means±s.e.m. (*P<0.05).
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assay revealed that the performance characteristics of the assay for
measurement of IGF-I in rabbits are in line with the standards for
human diagnostics outlined in the Clinical and Laboratory Standards
Institute recommendations, as well as in a recent consensus
statement (Clemmons, 2011; NCCLS, 2004).
However, the experiments using recombinant rabbit IGF-I, as well
as the measurements made using LC-MS/MS, suggest a reduced
affinity for rabbit IGF-I of one or both of the antibodies used in this
human IGF-I assay. The biochemical structure of rabbit and human
IGF-I is almost identical with the exception of a single amino acid
exchange at the C-terminal fragment (UniProt database: exchange
of serine to alanine in rabbit IGF-I at position 69). The capture
antibody of the IDS-iSYS IGF-I assay binds to the N-terminus
(Bidlingmaier et al., 2014) and thus should recognize human and
rabbit IGF-I to an equal extent. Most likely, the acridinium-labeled
antibody in the assay targets an epitope that includes the C-terminal
part of the IGF-I molecule, or the epitope is conformationally
changed by the one amino acid difference between both species.
This might offer a possible explanation as to why the recovery of
recombinant rabbit IGF-I was only around 50%. The assumption
that the difference in the amino acid sequences also translates into a
substantial difference in the 3D-structure of the IGF-I molecule is
also supported by the observation of the reduced bioassay activity
of the recombinant rabbit IGF-I tested in the human MCF7 cell line
(see Materials and Methods). In summary, the true IGF-I
concentrations in rabbits seem to be higher than those measured by
using the immunoassay and, presumably, are comparable to the IGF-
I concentrations observed in rodents (Bielohuby et al., 2013). Direct
evidence for this statement derives from the IGF-I measurements
made using LC-MS/MS, which clearly showed higher IGF-I
concentrations in all samples compared to those obtained from the
immunoassay. Owing to the limited number of samples analyzed
using both methods, this study cannot provide a definite conversion
factor for the immunoassay results. However, our data suggest that
the true IGF-I concentrations in rabbits are on average
approximately 1.9-fold higher than those measured by using the
immunoassay.
Of note, we have also previously tried to analyze IGFBP-3 in
rabbit samples using an assay running on the same automated
platform (Friedrich et al., 2014). However, we were not able to
detect IGFBP-3 in rabbit samples using the automated system.
Therefore, we investigated IGFBP concentrations by western
ligand blotting, using a novel approach for quantitative
determination of IGFBPs independent of the species (Laeger et al.,
2014; Metzger et al., 2011). In agreement with previously
published data from other groups (Nason et al., 1996; Wolf et al.,
1997), we confirmed that IGFBP-2 is the most abundant
circulating IGFBP in rabbits. Exogenous GH stimulated an almost
twofold increase of IGFBP-2 levels in rabbits, whereas, in humans,
serum concentrations of IGFBP-2 are suppressed by the
administration of GH (Bannink et al., 2006; Kassem et al., 1998;
Katz et al., 1996). This not only reveals a general difference in the
control of IGFBP-2 between humans and rabbits but identifies
IGFBP-2 as a sensitive indicator of the actions of GH in rabbits.
Importantly, IGFBP-2 concentrations showed a highly significant
correlation with those of IGF-I in the serum of rabbits, which was
much less pronounced for IGFBP-4 or even absent for IGFBP-3.
This is in line with data from Wolf and colleagues who show
higher IGFBP-2, but not IGFBP-3 and IGFBP-4, concentrations in
rabbits overexpressing IGF-I (Wolf et al., 1997). So far, only a few
reports on circulating IGFBP concentrations have been published
for rabbits. One study reports a decline of all serum IGFBPs in
early pregnancy compared with non-pregnant rabbits, as measured
by using semi-quantitative western-ligand blotting, with a strong
increase in IGFBP concentrations by mid-gestation until the late
pregnancy (Nason et al., 1996). Interestingly, the intensities of the
detected IGFBPs (IGFBP-2, IGFBP-3 and IGFBP-4) paralleled the
changes in concentrations of serum IGF-I and IGF-II during
pregnancy, suggesting that rabbits also display a molar ratio of
approximately 1:1 for IGFs and IGFBPs (Nason et al., 1996). In
our study, changes in serum IGFBP-2 reflected the biological
differences of circulating IGF-I, as seen, for example, in the
parallel increase of IGF-I and IGFBP-2 after recombinant human
GH treatment or in 4- and 6-month-old female rabbits, which
showed higher IGF-I and IGFBP-2 concentrations when compared
to male rabbits of the same age. Our results highlight that IGF-I
concentrations in rabbits are influenced by age, sex and genetic
background. Although never systematically analyzed in rabbits
before, this is not surprising, because these factors are known
variables for IGF-I concentrations in mammals (Bidlingmaier et
al., 2014; Le Roith et al., 2001). By contrast, owing to the fact that
rabbits are widely used in biomedical research, it is surprising that
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Fig. 3. Serum IGF-I and IGFBP-2 in 1- to 6-month-old rabbits. (A) Serum
IGFBP-2 concentrations (being the most abundant circulating IGFBP in
rabbits) and (B) serum IGF-I concentrations in 1-, 2-, 3-, 4- and 6-month-old
male (blue dots) and female (red dots) NZW rabbits (n=10 per sex and age
group). Each dot represents one serum sample; the black lines indicate
means±s.e.m. for each sex and age group, respectively (means with the
s.e.m. bars ‘up’, females; means with the s.e.m. bars ‘down’, males). For
illustrative purposes, the statistical comparison of age groups by using
ANOVA is shown in the respective section of the results only.
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only a few studies have investigated serum IGF-I and IGFBP
concentrations in rabbits.
In 1984, D’Ercole et al. reported that they had developed and
validated a radioimmunoassay (RIA) for the measurement of IGF-I
in rabbit serum (relative to a human standard serum) (D’Ercole et
al., 1984). The authors investigated IGF-I levels in pregnant and
non-pregnant NZW rabbits. There were no significant differences
between pregnant and non-pregnant rabbits, and the measured
concentrations ranged between 4 and 7 U/ml. When employing a
conversion factor of 150 ng/ml per 1 U/ml IGF-I (Festoff, 1995), our
measurement results in NZW female rabbits were similar to those
reported by D’Ercole and colleagues (D’Ercole et al., 1984).
However, the RIA developed by D’Ercole et al. has not been
validated with respect to linearity, precision or recovery and, to the
best of our knowledge, no further studies measuring rabbit IGF-I
with this assay have been published thereafter. Using the Nichols
Research Institute human IGF-I RIA, which is no longer available,
Turner et al. measured IGF-I in the serum of 3.5-month-old female
Dutch-Belted rabbits to investigate whether oral fluoride
supplementation affected skeletal growth factors (Turner et al.,
1997). The authors of this study showed IGF-I concentrations
between 66 and 92 ng/ml. Costa et al. generated transgenic rabbits
overexpressing bovine GH (bGH) and measured IGF-I by using the
human IGF-I RIA from Nichols (Costa et al., 1998). In their study,
control rabbits had mean IGF-I concentrations of 149 ng/ml, the
rabbits that overexpressed bGH showed approximately 4.5-fold
higher circulating levels of IGF-I. Nason and co-workers
systematically investigated serum IGF-I in NZW rabbits during the
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Fig. 4. Effect of treatment with recombinant GH or a GHA on serum IGF-I and IGFBP-2. (A) Concentrations of serum IGF-I and (B) circulating
concentrations of the growth hormone antagonist Pegvisomant (GHA) in GHA-treated rabbits. The green arrows indicate the injection time points (1 mg/kg of
body weight). Controls received equal volumes of PBS. Serum samples were collected before injection at baseline (0 h) and 24, 48, 72, 96, 120, 144 and 168 h
after the first GHA injection. Concentrations of (C) serum IGF-I and (D) circulating concentrations of recombinant human growth hormone (rhGH) in rabbits that
had been treated with recombinant human GH. The green arrows indicate the injection time points (1 mg/kg of body weight). Controls received equal volumes
of PBS. Serum samples were collected before injection at baseline (0 h) and 4, 8, 24, 48, 56 and 72 h after the first injection of recombinant human GH.
(E) Concentrations of circulating IGFBP-2 in rabbits that had been treated with recombinant human GH (red line), GHA (blue line) or PBS (black line). Data
were analysed by using two-way ANOVA with subsequent Bonferroni correction for multiple-comparison post-hoc tests. Data are presented as means±s.e.m.
(#P=0.054, *P<0.05, **P<0.01).
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course of pregnancy by using the RIA (Nason et al., 1996). Non-
pregnant rabbits showed mean IGF-I concentrations of 498 ng/ml,
which peaked at day 21 of gestation, followed by a decline to 341
ng/ml by day 30. Other authors have only sporadically measured
IGF-I in different rabbit model systems, reporting IGF-I
concentrations between 87 and 170 nmol/l in NZW rabbits (Schiller
and McNamara, 1999), between 8 and 16 ng/ml in male and female
Japanese rabbits [measured with an IGF-I RIA from Coulter Co. Ltd
(Fu et al., 2007)], between 17 and 123 ng/μl in NZW rabbit fetuses
of the control groups during days 21 and 31 of gestation [measured
with a human IGF-I RIA from Diagnostic Systems Laboratories
(Thakur et al., 2000)], and between 245 and 371 ng/ml in 30-day-
old male and female NZW rabbits [measured with an IGF-I RIA
from the Tianjin Juding Company (Zhang and Li, 2010)]. Taken
together, the above cited studies reflect the large degree of
heterogeneity in measurement methods, the lack of standardization
for measurement of IGF-I in rabbits and the need for a systematic
evaluation of physiological IGF-I concentrations in rabbits.
Our current study systematically investigated circulating IGF-I
concentrations in rabbits of both sexes, between 1 and 6 months of
age and from two genetic strains using a validated IGF-I
immunoassay. This data set represents a solid basis for the
physiological regulation of IGF-I in rabbits and can, additionally,
provide a reference point for future studies measuring IGF-I in rabbits.
We have demonstrated that female rabbits of the NZW and CB strains
have significantly higher IGF-I concentrations compared with those
of age- and strain-matched male rabbits. In our study, the differences
between sexes became significant in NZW rabbits aged 3 months and
older. Puberty in rabbits is initiated after ~2 months of age (Berger et
al., 1982). IGF-I concentrations were highest in 1- and 2-month-old
rabbits and declined thereafter in both sexes, being significantly lower
at 6 months compared with 1- or 2-month-old rabbits. With respect to
age and IGF-I concentrations, the timing in rabbits is similar to that
in humans, in which the highest IGF-I concentrations are also found
during puberty (Bidlingmaier et al., 2014).
Our data indicate that rabbits, in contrast to rodents (Bielohuby et
al., 2011b), are a suitable alternative animal model in which to test
novel GH agonists and antagonists because they show a human-like
response in changes of IGF-I concentration when treated with
recombinant human GH and a GHA. Because the amino acid
sequence of secreted GH is highly conserved throughout most
mammalian species (including rabbits) (Wallis and Wallis, 1995), it
is likely that treatment with GH preparations from other species (e.g.
porcine or bovine GH) also increases serum IGF-I concentrations in
rabbits. Rabbits could be especially useful to investigate the
pharmacodynamics of GHAs because the previously generated
bGH-overexpressing rabbit model shares many similarities with the
pathophysiological metabolic, histological and anatomical
alterations – including acromegalic lesions and insulin resistance –
that are frequently seen in individuals with acromegaly (Costa et al.,
1998). By contrast, it has been pointed out that GH-overexpressing
mouse lines are not a suitable model to study human acromegaly
because, although they display a giant phenotype, the typical
pathophysiological alterations associated with acromegaly are absent
or less pronounced in rodents (Costa et al., 1998). Similarly, GH-
overexpressing pigs do not display the sclerotic pathophysiology
that is observed in individuals with acromegaly (Pinkert et al.,
1994). The acrogemalic phenotype observed in GH-overexpressing
rabbits together with the human-like pharmacodynamic properties
of IGF-I in rabbits, including their responsiveness to exogenous
treatment with recombinant GH and GHAs, renders the rabbit as a
valuable research model for this field.
In summary, our experiments have shown that IGF-I
concentrations in rabbits display pharmacodynamic behaviors
similar to those in human in response to treatment with exogenous
recombinant human GH and a GHA. Because IGF-I is not a suitable
pharmacodynamic parameter to monitor the action of exogenous
GH in rodents, our results open up the possibility to use rabbits in
combination with measurements of IGF-I concentration as a new
laboratory animal model to develop new GH agonists. Furthermore,
rabbits showed a human-like decline of serum IGF-I levels in
response to treatment with the GHA Pegvisomant at doses
comparable to those used in the clinic, thus enabling research using
rabbits on novel therapeutic options for the treatment of pathological
GH excess. Similar to other mammals, including humans, rabbits
display variations in IGF-I concentrations depending on sex, age and
genetic background. Our data on IGFBPs indicate that IGFBPs also
play an important biological role in rabbits, but with species specific
differences – IGFBP-2 instead of IGFBP-3 is the most abundant
IGFBP in rabbits. Furthermore, IGFBP-2 is a good marker for
treatment with exogenous recombinant human GH, but not for GHA
administration. Second, our assay validation experiments together
with the LC-MS/MS data have shown that the human IDS-iSYS
automated IGF-I assay can serve as a reliable platform for high-
throughput analyses of IGF-I in rabbit serum. The true IGF-I
concentrations are approximately twofold higher than the results
obtained using the immunoassay, most likely because of a lower
binding affinity of the labeled antibody in this human IGF-I
immunoassay. By using this automated system, translational
research can be facilitated and this might aid development of novel
therapeutics to treat pathological conditions of the GH-IGF system.
MATERIALS AND METHODS
Validation of the iSYS IGF-I immunoassay for measurement of
rabbit IGF-I
Serum samples and reagents
The validation of the IDS-iSYS IGF-I immunoassay (IDS, Boldon, UK)
for measurement of rabbit IGF-I was performed using commercially
available rabbit serum samples (Charles-River, Sulzfeld, Germany).
Following sample delivery on dry ice, several aliquots were immediately
prepared and stored at −80°C until analysis. For the analysis of matrix
RESEARCH ARTICLE Disease Models & Mechanisms (2014) doi:10.1242/dmm.016519
Fig. 5. Changes in the body weight of rabbits before the start of
treatment with recombinant human GH or a growth hormone antagonist
(GHA) and after termination of the treatment protocols. Data were
analysed by using ANOVA with subsequent Bonferroni correction for
multiple-comparison post-hoc tests. Data are presented as means±s.e.m.
(*P<0.05, **P<0.01).
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effects on the automated system, rabbit serum samples and ten random
native human serum samples, which remained after routine diagnostic
analyses (‘remnant’), were used. All human serum samples derived from
a study which had been approved by the respective local institutional
review board, and informed consent was obtained from participants. The
source of recombinant human IGF-I (10 mg/ml) was Increlex® (Ipsen,
Ettlingen, Germany). Custom-made recombinant rabbit IGF-I (0.5 mg/ml)
was prepared by Protein Laboratories Rehovot (PLR, Rehovot, Israel). The
recombinant rabbit IGF-I protein was overexpressed in Escherichia coli
as insoluble protein, refolded and purified to homogeneity as a monomeric
protein by using anion-exchange chromatography followed by size
exclusion chromatography (analytical purity >95%; monomer content
>90%). Initially, the recombinant rabbit IGF-I concentration was
determined by reading the absorbance at 280 nm and employing the
computer programs of DNAman and/or the PC GENE computer analysis
program of protein sequences (IntelliGenetics, Hilton Head, SC, USA).
Recombinant rabbit IGF-I is biologically active when compared to human
IGF-I. The 50% effective dose (ED50), calculated by the dose-dependent
proliferation of human MCF7 cells is 5 to 25 ng/ml in the cell culture
mixture, depending on culture conditions. Its activity is 30-40% compared
to that of human IGF-I. A single production batch of the recombinant
rabbit IGF-I was used for all analyses. When preparing the working
solution for the recovery experiments using recombinant rabbit IGF-I, all
recombinant rabbit IGF-I concentrations (based on the manufacturer’s
data) were independently confirmed by LC-MS/MS analyses, as stated in
the relevant Materials and Methods section.
Assay validation
All IGF-I measurements were performed on the iSYS IGF-I immunoassay
using the supplied reagents and following the manufacturer’s assay
instructions [further assay details have been published previously by
Bidlingmaier et al. (Bidlingmaier et al., 2014)]. A validation of assay
precision, sensitivity, linearity and recovery in rabbit serum was performed
according to standard recommendations. For the analysis of the intra-assay
precision, ten repeated measurements of IGF-I in six native rabbit sera
displaying low, medium and high IGF-I concentrations were performed. The
precision in the low range was determined using an additional five native
rabbit samples with previously measured (i.e. known) IGF-I concentrations.
These five samples were divided into four aliquots each and diluted with
assay buffer [containing NaCl, Tris-aminomethane, NaN3, Tween-40,
BSA:BSA, bovine γ-globulin and diethylenetriaminepetaacetic acid
(DTPA)] to obtain samples to yield expected IGF-I concentrations between
20 and 25, 15 and 20, 10 and 15, and 5 and 10 ng/ml. Measurement of IGF-
I was repeated ten times in each diluted sample, to obtain a total of 200 IGF-
I measurements. Mean coefficients of variation from these ten measurements
were calculated. The inter-assay variability was investigated in six native
rabbit samples (low, medium and high IGF-I concentrations, singlicate
measurements) in which IGF-I concentrations were measured over five
different assay runs (on five measurement days). Dilution linearity was
tested in two low and high rabbit sera (serum A and B, see Table 2) and in
two low and high human samples (serum A and B, see Table 2) with IGF-I
concentrations between 15 and 585 ng/ml (rabbit) and 12-527 ng/ml
(human). IGF-I concentrations were then measured in native rabbit and
human samples, and in samples which had been diluted serially 1 in 2 with
assay buffer. In a second experiment, three random native rabbit samples
were serially diluted with assay buffer and measured in relation to serial
dilutions of the reference materials (recombinant rabbit IGF-I and
recombinant human IGF-I). For the dilution of the reference material and
generation of the standard curves, serial dilutions of recombinant rabbit IGF-
I and recombinant human IGF-I dissolved in assay buffer were used (range:
recombinant rabbit IGF-I, 8-370 ng/ml; recombinant human IGF-I, 19-1027
ng/ml). For the analysis of recovery, aliquots with the indicated amounts of
recombinant rabbit IGF-I were prepared (dissolved in assay buffer) and
measured. The ratio of the observed over the expected concentrations (i.e.
recovery) is displayed as a percentage in Table 3. Recovery was also
investigated by using recombinant human IGF-I (dissolved in assay buffer)
and by spiking human and rabbit serum samples with recombinant rabbit
IGF-I.
Analysis of IGF-I by using LC-MS/MS
In a subset of rabbit samples, IGF-I was also measured by using LC-MS/MS
as described in detail recently (Cox et al., 2014). Furthermore, concentrations
of recombinant rabbit IGF-I in the working aliquots for the recovery
experiments were independently confirmed by using LC-MS/MS analyses to
yield expected IGF-I concentrations between 12.6 and 3780 ng/ml.
Analysis of IGFBPs by western ligand blotting in rabbit serum
IGFBPs were analyzed in all sera of rabbits from different genetic
backgrounds, age groups and both genders, as well as in a subset of samples
from the recombinant human GH and GHA experiments (samples from time
points 0, 24, 72 and 168 h after the first injection with the indicated
substance) by using quantitative western ligand blot analysis, as described
previously (Hossenlopp et al., 1986; Laeger et al., 2014). Briefly, serum
samples and serial dilutions of recombinant human IGFBP standards (R&D
Systems, Wiesbaden, Germany) were diluted 1 in 20, boiled in sample
buffer [312.5 mM Tris (pH 6.8), 50% (w/v) glycerol, 5 mM EDTA (pH 8),
1% (w/v) SDS and 0.02% bromophenol blue] for 5 minutes. Proteins were
separated by using SDS-PAGE followed by the transfer onto a
polyvinylidene fluoride membrane (Millipore, Bedford, USA). The blots
were blocked and then incubated with biotin-labeled human IGF-II (1 in
500; BioIGF2-10; ibt-systems, Binzwangen, Germany). The binding
proteins were detected by using enhanced chemiluminescence using
LuminataTM Forte (Millipore, Bedford, USA). Bands were visualized on a
KODAK Image Station 4000MM (Molecular Imaging Systems, Carestream
Health, New Haven, USA) and quantified by using ImageQuant 5.2
software (Molecular Dynamics). Signal intensities were corrected for
background and quantified by using human recombinant standards as
calibrators (R&D Systems, Wiesbaden-Nordenstadt, Germany) on each blot.
Curve fitting was performed by using a four parametric nonlinear regression
(HILL equation) of each separate IGFBP. The calculation of the IGFBP
concentrations in serum was performed using the software GraphPad Prism4
and corrected for dilution and volume per lane of each sample. The inter-
assay coefficients of variation for IGFBP-3, IGFBP-2 and IGFBP-4 were
between 6% and 21%.
Analysis of biological variability in rabbit samples
For the analysis of biological variability of IGF-I concentrations in rabbits,
IGF-I concentrations were measured in the serum of male and female rabbits
from two different strains of (NZW and CB) rabbit (13-weeks-old, n=7 male
and n=8 female for each strain). Furthermore, IGF-I was measured in serum
samples of male and female NZW rabbits [Crl:KLB(NZW)] which were 1, 2,
3, 4 and 6 months old (n=10 per sex and age group). In addition, serum IGF-
I concentrations were determined in 30 serum samples of 1- and 6-month-old
male and female NZW rabbits by using LC-MS/MS analysis, as recently
described (Cox et al., 2014). All native serum samples were purchased from
an animal supplier (Charles-River, Sulzfeld, Germany). Rabbits were housed
in the company’s building (Charles-River) and blood samples were custom-
collected from the rabbits’ ear veins for this purpose by skilled company staff
members. Following sample delivery on dry ice, several aliquots were
immediately prepared and stored at −80°C until analysis.
Effects of treatment with GH and a GHA on intact rabbits
All experiments involving the treatment of rabbits with GH and a GHA were
conducted at the University of Isfahan, Isfahan, Iran. For this purpose, male
NZW rabbits aged 30 weeks with an initial body weight of 2100±266 g
(mean ± s.d.) were purchased from the Pasteur Institute (Tehran, Iran). Two
rabbits were housed per cage at a temperature of 23±2°C and a relative
humidity of 45±10%. All animals were allowed free access to water and a
commercial rabbit pellet diet supplied by the Pasteur Institute. All animal
experiments were approved by the local ethical committee of the University
of Isfahan.
Rabbits were randomly divided into three groups seven days before the
start of the study. Rabbits received subcutaneous injections of either
recombinant human growth hormone (recombinant human GH, Norditropin;
Novo Nordisk), growth hormone antagonist Pegvisomant (Somavert, Pfizer)
or phosphate buffered saline, PBS (CMG, Iran) at 9 am every day, or as
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indicated in the protocol (for multiple injections). The Norditropin and
Somavert solutions were prepared according to the manufacturer’s
recommendations and further dilutions were made, if necessary, using PBS
to obtain the injection concentration of 2.5 mg/ml. Rabbits were injected
with 1 mg per kg of body weight of the relevant drug or with equal volumes
of PBS (recombinant human GH, n=6 per group; GHA, n=10 per group).
Blood samples were taken from the ear veins before administration of drugs
or at the specified time points. Injections of recombinant human GH were
performed directly after sampling the baseline blood sample (0 h) and 48 or
56 h after the first injection. Blood samples for the experiments involving
recombinant human GH were collected at baseline, as well as 4, 8, 24, 48,
56, 72 h after the baseline sample. For the experiments involving
Pegvisomant, rabbits were injected with this GHA after collecting the
baseline sample (0 h) and at six additional time points in 24 h intervals (after
24, 48, 72, 96, 120 and 144 h). Blood samples for these experiments were
collected at baseline, as well as 24, 48, 72, 96, 120, 144, 168 h after the
baseline sample. Blood samples were allowed to clot at room temperature
for 1 h, centrifuged and stored at −80°C before shipment on dry ice to be
assayed. Body weight measurements were performed using a digital scale
(Sartorius) before injection or blood sampling. Serum samples were then
used to measure circulating IGF-I with the automated iSYS immunoassay
as described above. Furthermore, circulating concentrations of Pegvisomant
or recombinant human GH were analyzed in rabbit samples using a time-
resolved fluorescence assay. Detailed descriptions of this method have been
published elsewhere (Veldhuis et al., 2002; Veldhuis et al., 2010).
Statistical analysis
Statistical analysis was performed using the SPSS software package (SPSS,
version 15.0, Chicago, USA), Microsoft Excel and GraphPad Prism
(GraphPad Software, Version 5, La Jolla, USA). Non-parametric
Mann–Whitney U tests were used for statistical comparison between two
groups (e.g. IGF-I concentrations in male vs. female rabbits, Fig. 2) whereas
one-way (Fig. 5) and two-way ANOVA with subsequent Bonferroni
correction for multiple-comparison post-hoc tests was used for comparisons
between three or more groups (e.g. comparison of IGF-I concentrations in
different age groups or the effects of treatment with Pegvisomant on IGF-I;
Figs. 3, 4). Correlation analyses for the comparison of measurements
methods (immunoassay versus LC-MS/MS) and for the correlation analyses
of IGFBPs with serum IGF-I were performed by non-parametric Spearman’s
analysis and by Passing–Bablok regression. The Passing–Bablok
comparison was used to compare the two measurement methods
(immunoassay versus LC-MS/MS) because this non-parametric method
does not require a normal distribution of the data and is very robust against
the distribution of uncertainty between the two methods and individual
outliers. The cut-off for statistical significance was set at P<0.05. Unless
stated differently, all data are presented as means ± standard error of the
mean (s.e.m.).
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